Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Abstract : Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor signaling pathway [1, 2]. Remarkably, approximately two thirds of patients with relapsed/refractory (R/R) MCL treated with ibrutinib, the first-in-class BTK inhibitor, achieve a durable response [3–5]. However, ibrutinib treatment also commonly produces off-target adverse events (AEs) such as bleeding, atrial fibrillation, diarrhea, and infection.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-03383683
Contributeur : Nathalie Salvy-Córdoba Connectez-vous pour contacter le contributeur
Soumis le : lundi 18 octobre 2021 - 16:21:48
Dernière modification le : jeudi 19 mai 2022 - 15:56:02

Lien texte intégral

Identifiants

Collections

Citation

Simon Rule, Guillaume Cartron, Christopher Fegan, Franck Morschhauser, Lingling Han, et al.. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2020, 34 (5), pp.1458-1461. ⟨10.1038/s41375-019-0658-7⟩. ⟨hal-03383683⟩

Partager

Métriques

Consultations de la notice

15